10/21/2014 - 11:50 AM EST - Amorfix Life Sciences Ltd. : announced today that it has closed the first tranche of a non-brokered private placement pursuant to which 1,260,000 common shares of Amorfix and 1,260,000 Warrants were issued for gross proceeds of $352,800. The Company intends to use the net proceeds of the Offering to continue the development of its research programs including its cancer therapeutic program, ProMIS™ and its Alzheimer's disease and for general corporate purposes including the completion of ongoing discussions with multiple partners for a variety of business deals focused on the formation of strategic alliances and partnerships to advance the Company's therapeutic and diagnostic programs. Amorfix Life Sciences Ltd.
shares T.AMF are trading unchanged at $0.20.